Bausch Health Companies | VRX - Debt


Bausch Health Companies reported $20.78B in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Amgen USD 57.32B 2.72B Mar/2026
ANI Pharmaceuticals USD 613.76M 3.28M Mar/2026
Aurora Cannabis CAD 23.86M 76.48M Mar/2026
Bausch Health Companies USD 20.78B 16M Jun/2026
Biogen USD 8.09B 1.53B Jun/2026
Bristol-Myers Squibb USD 46.43B 711M Mar/2026
Canopy Growth CAD 278.71M 19.38M Mar/2026
Corcept Therapeutics USD 9.64M 3.53M Mar/2026
Danaher USD 26.56B 8.07B Jun/2026
Drreddys Laboratories INR 77.34B 9.61B Mar/2026
Eli Lilly USD 43.37B 867M Mar/2026
Gilead Sciences USD 22.17B 2.76B Mar/2026
Nektar Therapeutics USD 0 0 Jun/2022
Novo Nordisk DKK 118.72B 61.75B Mar/2025
Pacira USD 363.12M 4.53M Jun/2026
Perrigo USD 3.63B 7.7M Mar/2026
Phibro Animal Health USD 474.17M 730K Sep/2024
Prestige Brands USD 1.05B 33.86M Mar/2026
Supernus Pharmaceuticals USD 40.17M 733K Jun/2026
Vertex Pharmaceuticals USD 1.98B 8.9M Jun/2026
Zoetis USD 9.24B 0 Mar/2026